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Abstract
Background: MyD88 is the adaptor protein of MyD88-dependent signaling pathway of TLRs and IL-1 receptor and
regulates innate immune response. However, it was not clear whether and how MyD88 and related signaling pathways
in the dorsal root ganglion (DRG) and spinal dorsal horn (SDH) are involved in neuropathic pain.
Methods: Chronic constriction injury (CCI) was used to induce neuropathic pain in the rat. The expression of MyD88, TRIF,
IBA1, and GFAP was detected with immunofluorescent staining and Western blot. The expression of interleukin-1 beta
(IL-1β), high mobility group box 1 (HMGB1), NF-κB-p65, phosphorylated NF-κB-p65, ERK, phosphorylated ERK, and tumor
necrosis factor-alpha (TNF-α) was detected with Western blot. Pain-related behavioral effects of MyD88 homodimerization
inhibitory peptide (MIP) were accessed up to 3 weeks after intrathecal administration.
Results: Peripheral nerve injury significantly increased the protein level of MyD88 in the DRG and SDH, but had no effect
on TRIF. MyD88 was found partly distributed in the nociceptive neurons in the DRGs and the astrocytes and microglia in
the SDH. HMGB1 and IL-1β were also found upregulated in nociceptive pathways of CCI rats. Intrathecal application of MIP
significantly alleviated mechanical and thermal hyperalgesia in the CCI rats and also reversed CCI-induced upregulation of
MyD88 in both DRG and SDH. Further investigation revealed that suppression of MyD88 protein reduced the release of
TNF-α and glial activation in the SDH in the CCI rats.
Conclusions: MyD88-dependent TIR pathway in the DRG and SDH may play a role in CCI-induced neuropathic pain.
MyD88 might serve as a potential therapeutic target for neuropathic pain.
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Background
Neuropathic pain is associated with sensory abnormal-
ities and altered stimulus-response function, such as
allodynia, hyperalgesia, and loss of sensation in some
areas [1, 2]. The International Association for the Study
of Pain defined neuropathic pain as “pain caused by a
lesion or disease of the somatosensory nervous system”
(www.iasp-pain.org/Taxonomy#Neuropathicpain).
Neuropathic pain poses a heavy burden on the quality of
life of patients while currently available treatments are
often ineffective. The underlying molecular and cellular
mechanisms of neuropathic pain remain poorly eluci-
dated. There are increasing evidences indicating a role
of neuroimmune processes in the development of neuro-
pathic pain [3–6].
The myeloid differentiation factor-88 adaptor protein
(MyD88) is involved in Toll-like receptors (TLRs, except
for TLR3) signaling and interleukin-1 receptor (IL-1R)
signaling [7–10]. MyD88 mediates activation of TLRs or
IL-1R and leads to NF-κB activation, inflammatory cyto-
kines such as tumor necrosis factor-alpha (TNF-α) in
immune cells [8–10]. TLRs are danger-associated and
pathogen-associated molecular pattern receptors that
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regulate innate immunity via activated NF-κB-dependent
and mitogen-activated protein kinase (MAPK)-dependent
cytokine production [11, 12]. TLRs and IL-1R are not only
expressed on immune cells but also found on sensory
neurons in dorsal root ganglions (DRGs) and glial cells
(microglia and astrocytes) in the spinal cord [5, 13–17]. A
number of previous studies have found that TLRs in the
spinal cord played an important role in the model of
neuropathic pain and nerve injury, in which microglia and
astrocytes produced proinflammatory cytokines by activat-
ing TLRs [18–20]. Nociceptors of DRG that express TLRs
or IL-1R are also activated by LPS or inflammatory
cytokine interleukin-1β, inducing pain hypersensitivity [5,
18–22]. Recent publications show that MyD88, adaptor
protein of TLRs and IL-1R, is also found in the expression
in DRG and spinal cord [18–20].We hypothesized that
suppressed MyD88 adaptor protein in the DRG and spinal
cord could alleviate peripheral nerve injury-induced
neuropathic pain. Our findings reveal MyD88 adaptor
protein involved in the neuropathic pain and may provide




The adult male Sprague-Dawley rats (120–180 g) were
used in our study. All animals were housed (4–5 rats per
cage) in a standard 12-h light/dark cycle. These experi-
ments were approved by the Institutional Animal Care
and Use Committee in Chinese Academy of Medical
Sciences, Institute of Basic Medical Sciences. Animals
were randomly assigned to treatment or control groups.
Animal model of neuropathic pain
In accordance with the study of Bennett and Xie [23],
we performed chronic constriction injury (CCI) in the
rats anesthetized through intraperitoneal injection of
sodium pentobarbital (40 mg/kg) under aseptic condi-
tion. After the sciatic nerve of the mid-thigh level on
right side was exposed, four snug ligatures of chromic
gut suture were loosely tied around the nerve with about
1 mm space between the knots. The sciatic nerves of
sham animals were exposed without ligation.
Intrathecal catheterization and drug delivery
A PE10 catheter (length, 18 cm) was implanted intra-
thecally according to the protocol as described previ-
ously [24, 25]. Briefly, rats were anesthetized with
sodium pentobarbital (40 mg/kg) and a 2-cm longitu-
dinal incision was made above vertebrae L5–6.The
catheter with guide wire was inserted in the hole that
was made by a 23-gauge needle between lumbar verte-
brae L5 and 6. The catheter was pushed through the
intervertebral space until a sudden movement of tail or
the hindlimb was observed and then passed gently 2 cm
upward to reach the lumbar enlargement. The tip of the
catheter was fixed on the neck area of the rats. After
implantation, catheter localization was verified by intra-
thecal injection of lidocaine and all rats were observed
for a minimum of 5 days before being performed with
CCI surgery as described above. Rats showing motor
weakness or without catheter in spinal space were
excluded from the research. An intrathecal injection of
500 μM of MyD88 homodimerization inhibitory peptide
(MIP, Novus Biologicals, CO, USA) or control peptide
(Novus Biologicals, CO, USA) resolved in PBS was
administrated on preoperative and postoperative days. A
previous report showed that application of similar dose
of MIP did not induce any significant change in loco-
motor function in the rats [18].
Behavioral assessment of pain
All the behavioral measurements were carried out by an
experimenter blinded to schedule during 10 am–3 pm.
Mechanical allodynia was assessed by the up-down
method using calibrated Electronic von Frey (Electronic
von Frey 2393:II TC, USA). Rats were acclimated in
suspended cages with wire mesh floor. The probe was
applied perpendicularly to the paw with no acceleration
at a force and held for approximately 6–8 s. An acute
withdrawal of the paw was considered a positive re-
sponse. Thermal hypersensitivity was tested using plan-
tar test as described previously [24, 25]. The three
measurements of mechanic threshold or thermal latency
per side were averaged.
Western blot analysis
The L4–6 spinal dorsal horn and DRGs were harvested
from rats that were deeply anesthetized with sodium
pentobarbital (40 mg/kg) and snap-frozen in liquid ni-
trogen. Tissues were homogenized on ice in RIPA buffer
(20 mM Tris-HCl, 150 mM NaCl, 1% NP40, 1 mM
EDTA, 0.5% Na deoxycholate, and 0.1% sodium dodecyl
sulfate (SDS)) mixed with proteases inhibitor cocktail
and phosphatases inhibitor cocktail (Sigma-Aldrich,
MO, USA). After centrifuging, supernatants were
collected and denatured with SDS-PAGE loading buffer
consisting of 0.25 M Tris-HCl, 52% glycerol, 6% SDS,
5% β-mercaptoethanol, and 0.1% bromophenol blue for
5 min at 95 °C. Equal concentrations of lysates (30 μg)
were separated by SDS-polyacrylamide gel electrophor-
esis gels and transferred to a PVDF membrane (GE
Healthcare life science). After blocking with 5% BSA in
TBST (Tris-buffered saline with 0.1%Tween 20) for 1 h
at room temperature, membranes were incubated in
TBST overnight at 4 °C with primary antibodies. The
membranes were washed with TBST and then incubated
with secondary antibodies diluted with 5% skim milk in
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TBST for 1 h at room temperature (Table 1 lists the pri-
mary and secondary antibodies used for Western blot
analysis). Bands were detected with enhanced chemilu-
minescence reagents eECL Kit (CWBio, Beijing, China)
using an ImageQuant LAS 4000 mini Chemilumines-
cence imaging analysis system (GE Healthcare life
science, PA, USA), and the band densities were analyzed
using ImageJ software (NIH, USA). For the detecting of
total extracellular signal-regulated protein kinase (ERK)
or total NF-κB protein, we again blocked the same mem-
ber that was washed by Western blot antibody Stripping
Buffer (CWbio, Beijing, China) with 5% BSA in TBST
for 1 h at room temperature after detecting the phos-
phorylated ERK or phosphorylated NF-κB protein, incu-
bated the member with primary antibodies (anti-total
ERK or total NF-κB protein) overnight at 4 °C, and then
incubated with secondary antibodies for 1 h at room
temperature. Members that were re-incubated by
primary and secondary antibodies were detected with
enhanced chemiluminescence reagents eECL Kit using
ImageQuant LAS4000 mini Chemiluminescence imaging
analysis system.
Immunofluorescence staining
Rats were deeply anesthetized with sodium pentobarbital
(40 mg/kg) and then perfused with warm saline followed
by fresh 4% paraformaldehyde through the ascending
aorta. The L4–6 spinal dorsal horn (SDH) and DRGs
were collected, fixed in 4% paraformaldehyde for 4 h,
and then dehydrated in 30% sucrose overnight at 4 °C.
Tissues were mounted and finally cut to a thickness of
15 μm in a cryostat for immunofluorescent staining.
After blocking in 10% normal donkey serum and 0.2%
Triton X-100 in PBS for 1 h at room temperature, the
tissue sections were incubated overnight at 4 °C in 10%
normal donkey serum in PBS containing primary anti-
bodies and then incubated with the proper secondary
antibodies or Alexa Fluor 594-conjugated isolectin B4
(IB4) (1:100, Invitrogen/Thermo Fisher Scientific, USA)
for 1 h. The slides were then washed in PBS and cover-
slipped with VECTASHIELD Mounting Medium with
DAPI. Table 2 lists the primary and secondary antibodies
used for the immunofluorescence staining analyses. The
percentages of positive neurons to total neurons were
calculated and statistically analyzed. Images were
captured using a confocal laser scanning microscope
(FV1000, Olympus) and Olympus FluoView software. At
least 12 fields of view (×200) from three sections on
each ganglion were examined. DRG neurons were classi-
fied according to the cross-sectional areas of soma as
small- (area <636 μm2), medium- (area 637–1431 μm2)
and large-sized (area >1431 μm2). This classification is
based on the criteria as previously described [26].
Statistical analysis
Values were expressed as group mean and standard
errors (mean ± SEM) and analyzed using GraphPad
Prism 6 and SPSS software (version 17.0). For analysis of
Western blot, data were analyzed with one-way ANOVA
followed by Student-Newman-Keuls test. Behavioral data
were analyzed with two-way ANOVA. Chi-square tests
Table 1 List of primary and secondary antibodies used for Western blot analysis
Antibody Host Company Catalog number Dilution incubation conditions
MyD88 a rabbit Abcam ab2064 1:500 Overnight 4 °C
TRIF b rabbit Abcam ab13810 1:1000 Overnight 4 °C
IL-1β rabbit Proteintech 16806-1-AP 1:500 Overnight 4 °C
IBA1 rabbit Proteintech 10904-1-AP 1:500 Overnight 4 °C
TNF-α rabbit Sino Biological 80045-RP02 1:500 Overnight 4 °C
GFAP rabbit Cell signaling technology #12389 1:1000 Overnight 4 °C
HMGB1 rabbit Cell signaling technology #6893 1:1500 Overnight 4 °C
ERK rabbit Cell signaling technology #4695 1:2000 Overnight 4 °C
pERK rabbit Cell signaling technology #4370 1:1000 Overnight 4 °C
NF-κB rabbit Cell signaling technology #8242 1:1000 Overnight 4 °C
pNF-κB mouse Cell signaling technology #13346 1:1000 Overnight 4 °C
β-actin mouse Santa Cruz Biotechnology TA-09 1:1000 Overnight 4 °C
Anti-rabbit IgG horseradish peroxidase (HRP) Goat ZSGB-BIO ZDR-5306 1:3000 1 h RT
Anti-mouse IgG horseradish peroxidase (HRP) Goat ZSGB-BIO ZDR-5307 1:3000 1 h RT
a MyD88 antibody (Abcam, catalog #ab2064) was used for IHC or WB in 18 research articles (PubMed ID: 27389279, 26191134, 25446227, 26224622, 24307174,
24410883, 24477912, 24719558, 25187650, 23479602, 21278343, 20212458, 20837465, 20456021, 19553541, 17503341, 17114422, 16517734, 16461741)
b TRIF antibody (Abcam, catalog #ab13810) was used for IHC or WB in 11 research articles (PubMedID: 27389279, 26191134, 24146036, 22361049, 20511556,
19265160, 19648648, 19389833, 17503341, 17314314, 17000866)
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were used to compare between two or more incidence
of events. P < 0.05 was considered statistically significant.
Results
Up-regulation of MyD88 in nociceptive pathways after
CCI
First, we determined the time course of expression levels of
MyD88 in DRGs and SDH after CCI in rats. Our Western
blot results showed that CCI produced gradually rapid (in
3 days) and long-lasting (over 21 days) increase in the pro-
tein levels of in DRGs. MyD88 started increase from 3 days,
peaked at 7 days, and maintained to the highest level at
21 days after CCI (Fig. 1a) in DRGs. And the protein levels
of MyD88 were found produced and later increased to a
high level from 14 to 21 days in the SDH after CCI oper-
ation (Fig. 1b).
Similar to the result of Western blot, we found that
MyD88 were present at only very low levels in DRG and
SDH of naïve and sham operation rats with immuno-
fluorescence staining. Furthermore, by using immuno-
fluorescence, the MyD88 protein immunoreactivity was
found to be distributed in the three categories of
neurons: large-sized, medium-sized, and small-sized
neurons in DRG. We found a significant increase in the
Table 2 List of primary and secondary antibodies used for Immunofluorescence staining
Antibody Host Company Catalog ID Dilution incubation conditions
MyD88 rabbit Abcam ab2064 1:100 Overnight 4 °C
TRIF rabbit Abcam ab13810 1:200 Overnight 4 °C
IBA1 goat Abcam ab107159 1:200 Overnight 4 °C
GFAP goat Abcam ab53554 1:100 Overnight 4 °C
CGRP goat LifeSpan BioSciences LS-C122785 1:500 Overnight 4 °C
anti-rabbit IgG Alexa Fluor 488 donkey Jackson ImmunoResearch 711-545-152 1:400 1 h RT
anti-goat IgG Alexa Fluor 594 donkey Jackson ImmunoResearch 705-585-147 1:400 1 h RT
Fig. 1 CCI increase expression MyD88 in rat DRG and SDH. a and b Western blot analyses the time course for MyD88 expression in DRG (a) and SDH (b)
(n= 4 in each). Western blot analysis is shown on the top; quantification of protein levels (relative to naive group) is shown on the bottom. One-way
ANOVA, *P< 0.05 versus naive and sham. c Cellular distribution of MyD88 in DRGs. MyD88 was expressed in the large-, medium-, and small-sized neurons
(white arrows) sham to the CCI (top row). Double immunostaining shows coexpression of MyD88 with CGRP- and IB4-positive neurons, respectively (middle
and bottom rows). d Distribution and cellular of MyD88 in the SDH. MyD88 was distributed predominantly in the superficial layers (top row). MyD88 was
coexpression with astrocytes (GFAP, red) and microglial cells (IBA1, red) (middle and bottom rows). Scale bar: 20 μm (c, d)
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expression of MyD88 in DRG neurons (sham: 47.04%,
1049/2230; CCI 7 day: 67.30%, 1844/2740; CCI 14 day:
65.79%, 1579/2400) especially in small-sized neurons
(sham: 55.34%, 974/1760; CCI 7 day: 77.86%, 1744/2240;
CCI 14 day: 80.44%, 1448/1800) on days 7 and 14 after
CCI in DRGs (Fig. 1c and Additional file 1: Figure S1A-
B). The cellular localization of MyD88 in small neurons
of DRGs was determined by double immunofluores-
cence. In the nociceptive small neurons, staining of
MyD88 was colocalized in calcitonin gene-related pep-
tide (CGRP)-positive and nonpeptidergic isolectin B4
(IB4)-positive nociceptive neurons of DRGs (Fig. 1c). As
shown in the result of immunofluorescence, the expres-
sion of MyD88 was significantly upregulated in response
to CCI operation in the SDH of rats. And the MyD88
protein was dominated and distributed in the superficial
layers of the SDH. We also found that within 7 days
after CCI, MyD88 immunoreactivity was colocalized
with astrocytes (GFAP) and microglial cells (IBA1)
(Fig. 1d). These results suggest that MyD88 signaling
was activated in neurons of DRGs as well as SDH astro-
cytes and microglial cells after nerve injury.
CCI increases expression of IL-1β and HMGB1 in nocicep-
tive pathways
MyD88 is the downstream signaling adaptor protein of
Toll/interleukin-1 receptor (TIR) signaling and is
expressed in DRG and SDH. TLRs and IL-1R were also
found to express on primary sensory neurons of DRG
and glial cells in SDH [4, 5, 17, 21, 27, 28]. To define the
mechanism of MyD88-dependent TIR signaling in CCI,
we examined the expression of TLR2 and TLR4
endogenous ligand, high mobility group box 1 (HMGB1)
and IL-1R endogenous ligand, interleukin-1 beta (IL-1β).
Western blot showed CCI significantly increased pro-
tein levels of both pro-IL-1β and IL-1β in the DRG
(Fig. 2a). In the SDH, CCI induced significant upregula-
tion of the protein levels (from day 3 to day 7 after CCI)
of IL-1β, not pro-IL-1β (Fig. 2b). We then examined the
protein levels of HMGB. After CCI, protein expression
levels of HMGB1 in the DRG increased rapidly and sig-
nificantly from 1 day to lasting 21 days (Fig. 2c). The
levels of HMGB1 also greatly increased in the SDH of
CCI rat model (Fig. 2d).
Regulation and activation of NF-κB signal and ERK signal
in nociceptive pathways of CCI rats
The protein levels of both total NF-κB p65 and activated
phospho-NF-κB p65, in L4 and L5 DRGs, increased sig-
nificantly compared with naïve and sham groups. We
detected rapid and long lasting increase of the expres-
sion of total and activated phospho-NF-κB p65 in DRG
(Fig. 3a-b). Both total NF-κB p65 and activated
phospho-NF-κB p65 levels were found to peak at 3 days
after CCI and remained elevated to the 21 days, and did
not recover to the control level of naïve and sham after
CCI. Similar to the changes on DRGs, activated
phospho-NF-κB p65 as well as total NF-κB p65 also sig-
nificantly increased in SDH after CCI. Phospho-NF-κB
p65 were found to increase significantly and persistent
on all time points from 1 day to 21 days of CCI-induced
nerve injure compare with control group. Our results
demonstrated that total NF-κB p65 did not increase rap-
idly but showed an obvious increase at 7 to 21 days
Fig. 2 CCI increase expression IL-1β and HMGB1 in rat DRG and SDH. a and b Western blot analyses the time course for Pro-IL-1β and IL-1β
expression in DRG (A) and SDH (B). c-d Western blot analyses the time course for HMGB1 expression in DRG (C) and SDH (D). Western blot
analysis is shown on the top; quantification of protein levels (relative to naive group) is shown on the bottom. N = 4 in each group, One-way
ANOVA, *P < 0.05 vs. naive or sham
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compared with naïve and sham groups in SDH after CCI
(Fig. 3c-d). The expression of total NF-κB p65 on SDH
maximized at day 14 and maintained elevated to day
21after CCI-induced nerve injury.
Extracellular signal-regulated protein kinase 1/2 (ERK)
signal pathway was involved in TLR-mediated proin-
flammatory response. We found the protein levels of
both ERK1 (p44 MAPK, 44 kDa) and ERK2 (p42 MAPK,
42 kDa) increased significantly on all time points from 1
to 21 days after CCI in DRG (Fig. 3e, f ). Western blot
analysis also revealed activation of ERK in DRG and
SDH after CCI. A marked and persistent increase of
both phospho-ERK1 and phospho-ERK2 were observed
in DRG (3 to 21 days) and SDH (1 to 21 days) after CCI
(Fig. 3e–h).
MIP treatment relieve neuropathic pain after CCI
Compared with sham group, rats with CCI showed a
decrease in paw mechanical withdrawal threshold at
postoperative day (POD) + 3, achieving a significant dif-
ference at POD7, getting maximal at POD14 and thus
maintained throughout POD21 (Fig. 4a). The paw ther-
mal withdrawal latency of CCI group rats also decreased
significantly at POD7 and POD14 compared to that of
sham group (Fig. 4b). To determine the role of MyD88-
dependent signaling of TIR in CCI, we used MIP to
inhibit MyD88 dependent signaling. MIP was delivered
into the cerebrospinal fluid of lumbar enlargement by
intrathecal injection (500 μM in a volume of 20 μl in
rats).
We intrathecally administrated MIP and control pep-
tide daily from preoperative day −3 to day −1 (before
CCI). The results showed that MIP administration on
preoperative period delayed CCI-induced mechanical
allodynia and thermal hyperalgesia, with no effects in
sham operative rats (Fig. 4c, d). Then we injected MIP
and control peptide intrathecally daily for three consecu-
tive days (POD 3–5). We found that MIP administration
reversed the CCI-induced neuropathic pain and
produced long-lasting alleviative effects (POD 7–21) on
the mechanical allodynia and thermal hyperalgesia
(Fig. 4e, f ).
MIP treatment decrease expression level of MyD88
protein after CCI
Given that MyD88 expression increased significantly and
MyD88-NF-κB p65 signaling pathways activated postop-
eratively, we examined whether MyD88-dependent
signaling pathways could be suppressed by MIP treat-
ment, which relieved neuropathic pain in the CCI rats.
Our Western blot and immunofluorescent results
showed that the expression of MyD88 was significantly
Fig. 3 CCI induce NF-κB p65 and ERK signaling activation in rat DRG and SDH. a-b Western blot analysis shows time course for the expression of
total NF-κB p65 and activated phospho-NF-κB p65 in DRG (A). Quantification of protein levels of total NF-κB p65 and activated phospho-NF-κB
p65 in DRG (B). One-way ANOVA, *P < 0.05 versus naive and sham. c-d Western blot analysis shows time course for the expression of total NF-κB
p65 and activated phospho-NF-κB p65 in SDH (C). Quantification of protein levels of total NF-κB p65 and activated phospho-NF-κB p65 in SDH
(D). e-f Western blot analysis shows time course for the expression of total ERK and activated pERK in DRG (E). Quantification of protein levels of
total ERK and activated pERK in DRG (F). g-h Western blot analysis shows time course for the expression of total ERK and activated pERK in SDH
(G). Quantification of protein levels of total ERK and activated pERK in SDH (H). N = 4 in each group, One-way ANOVA, *P < 0.05 vs. naive or sham
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decreased in the L4–5 DRGs and SDH at day 14 after
intrathecally administered MIP to the CCI rats in com-
parison to rats that received the control peptide
(Fig. 5a–e and Additional file 1: Figure S1C).
Inhibition MyD88 suppresses activation of NF-κB signal
and ERK signal after CCI
NF-κB p65 and ERK signaling pathways were activated
at postoperation, we examined whether suppressed
MyD88 by MIP treatment could alter the activated situ-
ation of NF-κB p65 and ERK proteins in rats of CCI-
induced nerve injury. Our Western blot results showed
that the MIP treatment significantly decreased the phos-
phorylation of NF-κB p65 and ERK proteins in CCI-rat
SDH at day 14 after intrathecally administered MIP on
CCI rats in comparison to rats that received the control
peptide (Fig. 6a–d).
Inhibition MyD88-dependent pathway suppresses the
production of TNF-α and activation of astrocyte and
microglial cell
Glial cells, including astrocytes and microglial cells, play
a critical role in the initiation and maintenance of
neuropathic pain [4, 15, 29]. Nerve injury-induced acti-
vation of astrocytes and microglial cells act as modula-
tors in the maintenance of central sensitization. GFAP is
an astrocyte-specific marker that distinguishes from
other glial cells and also activation marker of astrocytes
in the CNS. IBA1 play as specific activated marker of
microglia in the CNS. Immunofluorescent results
showed CCI-induced activation of astrocytes (GFAP)
and microglia (IBA1) were suppressed by intrathecal
injection of MIP (500 μM on POD 3–5) (Fig. 7a).
CCI-induced increased expression of GFAP and IBA1
protein in the spinal cord SDH were also reduced by the
administration of MIP (Fig. 7b, c).
We also examined the expression of proinflamma-
tory cytokines TNF-α of SDH. After nerve injury,
the TNF-α was upregulated and played an important
role in the maintenance of neuropathic pain [30].
The significantly increased protein levels of TNF-α
induced CCI were suppressed greatly by intrathecal
injection of MIP in the SDH (Fig. 7b, c). These
results suggested that MyD88-dependent TIR signal-
ing played an essential role in the development of
neuropathic pain.
Fig. 4 Attenuated neuropathic pain by of MIP after CCI treatment. a-b CCI-induced mechanical allodynia (a) and thermal hyperalgesia (b).
Two-way ANOVA, *P < 0.05 versus sham. c-d Pre-intrathecal injection of MIP attenuated CCI-induced mechanical allodynia (c) and thermal
hyperalgesia (d) (each administration is indicated by an arrow on the 3, 2, and 1 days before CCI). e-f Mechanical allodynia (e) and
thermal hyperalgesia (f) is attenuated by MIP in the early phase of CCI operation (each administration is indicated by an arrow on the 3,
4, and 5 days after CCI). MIP (500 mM) was administrated i.t.in a volume of 20 μl; The control peptide was used in the control (Ctrl)
group. Nine rats were included in each group. Two-way ANOVA, *P < 0.05 vs. Sham + Ctrl or Sham + MIP, #P < 0.05 vs. Sham + Ctrl, Sham +
MIP or CCI + Ctrl
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Fig. 5 Intrathecal administration of MIP decreases MyD88 protein expression in rat DRG and SDH after CCI. a-b Western blot showing inhibitory effects of
MIP on CCI-increased protein level of MyD88 in DRG (A) and SDH (B). c Data summary of B. d-e Immunofluorescence showing inhibitory effects of MIP on
expression of MyD88 in DRG (D) and SDH (E). Scale bar: 20 μm (d, e). MIP (i.t., in a volume of 20 μl, 500 mM) was given once a day on postoperative days
3, 4, and 5, respectively. The control peptide was used in the control (Ctrl) group. Tissues were collected on postoperative days 14 (n = 4 each group).
One-way ANOVA, *P< 0.05 vs. Sham, #P< 0.05 vs. CCI + Ctrl
Fig. 6 Suppressed of NF-κB p65, ERK signal by inhibition of Myd88 in rat SDH after CCI. a Western blot showing inhibitory effects of MIP on CCI-induced
increased protein level of NF-κB p65 and pNF-κB p65. b Data summary of A. cWestern blot showing inhibitory effects of MIP on CCI-induced increased
protein level of ERK and pERK. d Data summary of C. Others are the same as Fig. 5
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Unchanged expression and distributions of TRIF in DRG
and SDH after CCI
Toll-like receptor signaling pathways were activated via
MyD88-dependent signaling transduction and MyD88-
independent signaling transduction pathway [8, 13].
Toll-receptor-associated activator of interferon (TRIF)
was the adaptor protein of MyD88-independent signal-
ing transduction pathway [7]. The results of Western
blot were observed that CCI had no effect on the protein
level of TRIF compared with naïve and sham operation
in L4–5 DRGs and SDH of rats (Additional file 1: Figure
S2A-B and Additional file 1: Figure S4A-B). The protein
presented in the neurons of DRGs and co-expressed
partly with CGRP and IB4-positive neurons (Additional
file 1: Figure S2C). In SDH, we found that TRIF distrib-
uted in the superficial layers. And astrocytes and micro-
glial cells partly expressed TRIF protein on SDH
(Additional file 1: Figure S2D). After CCI, unchanged
TRIF protein of DRGs and SDH may indicate that
MYD88-independent signaling transduction of DRGs
and SDH was not activated.
In addition, we performed experiments to test whether
MIP treatment could also decrease the expression of
TRIF in DRG and SDH. However, our Western blot and
immunofluorescent data showed that the expression of
TRIF was not affected in the DRG and SDH at POD 14
in MIP treatment CCI rats (Additional file 1: Figure
S3A-E and Figure S4C).
Discussion
In the present study, we explored the role of MyD88-
dependent TIR signaling pathways in the DRG and SDH
in a rat model of CCI-induced neuropathic pain. We
found that CCI induced a rapid and long-term upregula-
tion of MyD88 in the DRG and SDH of rat. Meanwhile,
the proinflammatory cytokine IL-1β and HMGB1 were
upregulated in the DRG and SDH. We also found that
phospho-NF-κB p65 and phospho-p44/42 MAPK of
Toll/interleukin-1 receptor downstream signal protein
were rapidly and long-lastingly upregulated in the DRG
and SDH after CCI. In contrast, CCI did not cause any
significant change in TRIF. Intrathecal injection of
MyD88 inhibitor MIP attenuated CCI-induced pain and
decreased MyD88 expression in DRG and SDH. Inhib-
ition of MyD88 suppressed the phospho-NF-κB p65,
phospho-p44/42 MAPK, the production of TNF-α, and
the activation of astrocytes and microglial cells in SDH.
These results suggested that MyD88-dependent TIR/NF-
κB p65 and p44/42 MAPK pathway, activated by IL-1β
and HMGB1, was involved in CCI-induced neuroinflam-
mation and neuropathic pain. In this study, we adminis-
trated MIP on preoperative days −3 to −1 (before CCI)
to achieve a maximum and sustaining effect of the drug.
Previous studies used a similar strategy of MIP applica-
tion to inhibit MyD88 in vitro or in vivo [31–33].
HMGB1 is a proinflammation mediator and endogen-
ous ligand of TLRs such as TLR2 and TLR4 [34].
HMGB1 can be induced in the DRG and/or SDH in
multiple animal models of pain [34–36]. IL-1β is a po-
tent proinflammatory cytokine and endogenous ligand of
IL-1R [21]. HMGB1 and IL-1β can activate calcium
mobilization in DRG neurons and stimulate astrocytes
or microglia cells to produce proinflammatory media-
tors or cytokines such as TNF-α via activation of NF-
kappa-B, MAPK, or other pathways [35, 37]. Previous
studies showed that intrathecal injection of HMGB1 or
IL-1β induced pain hypersensitivity including heat
hyperalgesia and mechanical allodynia [34, 37]. Release
of HMGB1 and IL-1β in the nociceptive pathway may
play a crucial role for the development of pain via influ-
encing adjacent neurons and glia [38]. In this study, we
also found that HMGB1 and IL-1β was robustly pro-
duced and sustained through POD 21 in the DRG and
SDH of CCI rats.
Fig. 7 Suppressed activation of glial cells and TNF-α production by inhibition of MyD88 in rat SDH after CCI. a Immunostaining showing inhibitory
effects of MIP on activation of microglial cells (IBA1), and astrocytes (GFAP). Scale bar: 20 μm. b Western blot showing inhibitory effects of MIP on
CCI-induced increased protein level of IBA1, GFAP, and TNF-α. c Data summary of B. Others are the same as Fig. 5
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TLRs play a pivotal role in innate immune responses.
Increasing evidence suggests that TLRs are expressed in
primary sensory neurons in DRG and TG [5]. TLR4
mainly express in small-diameter sensory neurons of
DRG and TG, which are mostly nociceptive sensor and
regulate nociceptive sensation such as pain [16, 20, 21].
Functional TLRs including TLR2 and TLR4 also express
in microglia and astrocytes that modulate glial activation
and spinal inflammatory of the spinal injury or chronic
pain-induced central sensitization [17, 39]. TLR4 medi-
ates the hyperalgesia and neuroinflammation by dam-
age/pathogen-associated molecular pattern components
such as heat shock protein 90 (HSP90), HMGB1, and
LPS [16, 21, 34, 35, 40]. Peripheral neurons of DRG or
glial cells of spinal cord may directly produce HMGB1
and/or HSP90 when peripheral and/or central nervous
system are damaged or administrated with drugs [18, 34,
35]. In this study, we measured total HMGB1 by West-
ern blots, while only disulfide HMGB1 is known to be a
TLR4 agonist [41, 42]. This problem will be addressed in
future studies. In addition, a recent study also found that
HMGB1 activates pro-inflammatory signaling via TLR5,
leading to allodynia [43]. Further experiments using spe-
cific TLR2 or TLR4 antagonists or knockout mice could
be performed to determine their roles in the MyD88-
dependent signaling pathway.
IL-1R was an important receptor for regulating im-
mune responses and inflammation [44]. It expresses
in nociceptive neurons of DRG and glial cells of SDH
and mediates interleukin-1 including interleukin-1β-
induced activation of cell [27, 28, 45]. IL-1β can act
directly on primary sensory neurons to evoke excita-
tory action on nociceptor neurons by IL-1R [28]. IL-
1β also activates IL-1R to contribute to hyperalgesia
and the establishment of peripheral and central
sensitization [28, 46].
Two distinct signaling transduction pathways of
TLRs were found [13]. Activated TLRs and/or IL-1R
signaling are involved in the recruitment of adaptor
molecules such as MYD88 or TRIF, then phosphoryl-
ate NF-kappa-B or MAPK via IL-1 receptor-
associated kinase1 (IRAK1) and TNF receptor-
associated factors6 (TRAF6) [7, 9, 10, 13]. MyD88 is
the adaptor protein of Toll/interleukin-1 receptor
(TIR) and plays an important role in the trafficking of
TIR signal pathway [7, 10]. MyD88 is expressed in
DRG neurons and glial cells and could be significantly
increased in the DRG from rat models of chronic pain
induced by chemotherapy [18]. SNL lesions produce
chronic pain is approximately 50% reduced in
MyD88-deficient mice [19, 47]. Consistently, intra-
thecal administration of MyD88 inhibitor suppresses
pain of paclitaxel-induced peripheral neuropathy
when applied 14 days after paclitaxel administration
[18]. TRIF is an adaptor protein of the MyD88-
independent signaling transduction pathways of TLRs
and shares mostly by TLR3 and TLR4 signaling [13].
The SNL-induced allodynia was significantly allevi-
ated in the MyD88 knock-out mice with reduced glial
activation in SDH and ATF3 expression in the DRG,
but these effects were not observed in the TRIF defi-
cient mice [47]. TRIF expression was found not sig-
nificantly changed in the SDH in a rat model of
paclitaxel-induced peripheral neuropathic pain [18].
Our results also showed a lack of change in TRIF pro-
tein in the DRG and SDH of CCI rats. Detailed mech-
anisms for the upregulation and activation of MyD88
without increases in TRIF with TLR signaling should
be further investigated in the future.
Conclusions
In this study, we found that peripheral nerve injury trig-
gered the upregulation of IL-1β and HMGB1, which
could bind to their receptors in the DRG and SDH and
transmit signals via adaptor protein MyD88. MyD88
may subsequently act through phosphorylated NF-κB
and ERK to regulate the expression of proinflammation
Fig. 8 Schematic illustration demonstrates MyD88-dependent signaling
pathways of neuropathic pain induced by CCI. Nerve injury produces
abundant HMGB1and IL-1β in the DRG and SDH. The binding of HMGB1
and IL-1β to their receptors (TLR2/4 andIL-1R, respectively) activates
MyD88 in the DRG and SDH, which phosphorylate NF-κB p65 and ERK.
Phosphorylated NF-κB p65 subsequently enter the nucleus to regulate the
expression of proinflammation cytokines such as TNF-α. Phosphorylated
ERK enter the nucleus to induce transcription factors such as AP-1, which
regulates the expression of certain cytokines and activates glial cells. All
these signaling events consequently result in central and peripheral
sensitizations that produce neuropathic pain
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cytokines and activate glia cells. MyD88-dependent TIR
pathway may play a role in CCI-induced neuroinflam-
mation and neuropathic pain. A schematic illustration
for the proposed MyD88-dependent signaling pathways
of neuropathic pain was provided in Fig. 8 This study
might suggest a potential strategy for the treatment of
neuropathic pain targeting MyD88.
Additional file
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S2 Unchanged expression and cellular distributions of TRIF protein in rat
DRG and SDH after CCI. Figure S3 Protein level of TRIF by intrathecal
administration of MIP in rat DRG and SDH after CCI. Figure S4
Quantification analysis from Immunofluorescence staining results of TRIF-
positive neurons in DRGs.
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